40359-34-0

Basic information

• Product Name: METHYL (2-FORMYLPHENOXY)ACETATE
• Synonyms: CHEMBRDG-BB 6497335;METHYL (2-FORMYLPHENOXY)ACETATE;AKOS B028929;Methyl 2-(2-formylphenoxy)
• CAS NO: 40359-34-0
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.18
• EINECS: 604-604-1
• Mol File: 40359-34-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 307.9°C at 760 mmHg
• Flash Point: 135.4°C
• Appearance: /
• Density: 1.201g/cm³
• Vapor Pressure: 0.000702mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: METHYL (2-FORMYLPHENOXY)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (2-FORMYLPHENOXY)ACETATE(40359-34-0)
• EPA Substance Registry System: METHYL (2-FORMYLPHENOXY)ACETATE(40359-34-0)

Safety Data

• Hazardous Substances Data: 40359-34-0(Hazardous Substances Data)

Usage

General Description

Methyl (2-Formylphenoxy) acetate is a chemical compound often used in organic synthesis. The formula for the compound is C10H10O4, and it typically presents itself as a colorless to light yellow liquid. It belongs to the class of organic compounds known as phenylacetic acid esters which are characterized by an ester group substituted at the O4-position of a phenylacetic acid or a derivative thereof. It is characterized by a sweet, fruity odor similar to honey, and has the potential for use across various industries including the flavor and fragrance industry due to its unique scent profile. As is true for many chemicals, it should be used with caution since potential toxicity or safety concerns haven't been fully investigated.

InChI:InChI=1/C10H10O4/c1-13-10(12)7-14-9-5-3-2-4-8(9)6-11/h2-6H,7H2,1H3

Upstream product

• 90-02-8 salicylaldehyde 
• 96-34-4 methyl chloroacetate 
• 89-95-2 2-methyl-benzyl alcohol 
• 96-32-2 bromoacetic acid methyl ester 
• 67-56-1 methanol 
• 6280-80-4 2-Formylphenoxyacetic acid 

Downstream Products

• 1646-27-1 methyl benzofuran-2-carboxylate 
• 1451409-01-0 5-(1-isopropyl-1H-tetrazol-5-yl)-4-(3-(trifluoromethyl)benz-yl)-4,5-dihydrobenzo[f ][1,4]oxazepin-3(2H)-one 
• 1451409-00-9 5-(1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl)-4-(4-fluoro-benzyl)-4,5-dihydrobenzo[f][1,4]oxazepin-3(2H)-one 
• 1451408-98-2 5-(1-cyclopentyl-1H-tetrazol-5-yl)-4-(2,5-dimethoxybenzyl)-4,5-dihydrobenzo[f ][1,4]oxazepin-3(2H)-one 

Relevant articles and documents

Bifunctional building blocks in the Ugi-azide condensation reaction: A general strategy toward exploration of new molecular diversity

1,5-Disubstituted tetrazoles are an important drug-like scaffold known for their ability to mimic the cis-amide bond conformation. The scaffold is readily accessible via substitution of the carboxylic acid component of the Ugi multi-component reaction (MCR) with TMSN3 in what is herein denoted the Ugi-azide reaction. This full paper presents a concise, novel, general strategy to access a plethora of new heterocylic scaffolds utilizing tethered aldo/keto-acids/esters in the Ugi-azide reaction followed by a ring closing event that generates novel highly complex bis-heterocyclic lactam-tetrazoles. The Royal Society of Chemistry.

Potash alum [KAL(SO4)2.12H2O] catalysed esterification of formylphenoxyaliphatic acids

A convenient and clean procedure for esterification is reported. Direct condensation of formylphenoxyaliphatic acids with low to high boiling alcohols catalysed by potash alum gave moderate to good yields. This catalyst could be recovered and reused without substantial loss in its catalytic activity and the methodology could be used for a range of closely related substrates.

Compounds for treatment of cardiac arrhythmia synthesis, and methods of use

The subject invention pertains to novel compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. The new compounds can have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The product can also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.